Is BPC-157 Banned in Sports? 2026 WADA and USADA Rules Explained

BPC-157 is not listed by name on the 2026 WADA Prohibited List, but it is treated as prohibited in-competition and out-of-competition under category S0 “Non-approved substances.” Any athlete who uses BPC-157 without an approved Therapeutic Use Exemption (TUE) risks an anti-doping violation, because laboratories are instructed to report this peptide when detected. USADA follows the same interpretation, so a positive test can bring suspensions of two to four years. Athletes should discuss safer recovery options with a sports-medicine physician before considering BPC-157.

• BPC-157 is classified under WADA’s S0 category because it has no FDA or global regulatory approval.
• USADA athlete advisories list BPC-157 as a prohibited peptide despite its growing prescription use in some countries.
• World Anti-Doping Code rules apply 24 hours a day, so using BPC-157 in the off-season can still trigger a ban.
• At least three combat-sport athletes have received two-year sanctions since 2023 for BPC-157 positives publicly disclosed by USADA and other agencies.

What BPC-157 Is and Why Athletes Use It

BPC-157 is a 15-amino-acid fragment of a gastric protein that shows tissue-healing effects in animal studies (Vasireddi et al., 2025). Pre-clinical data suggest it may speed tendon, ligament, and muscle repair, which explains why injured athletes search for it. However, only one uncontrolled human case series and no randomized trials exist (Mayfield et al., 2026). BPC-157 is not approved by the U.S. Food and Drug Administration, so any product is compounded or sold for “research.”

Peptide legality in the U.S. changed in July 2026, when HHS adopted an enforcement discretion policy for six peptides, including BPC-157. That policy lets 503A pharmacies compound the peptide for patients with a prescription but does not make it FDA-approved.

Rx.com now offers prescription BPC-157 compounded by a licensed U.S. 503A pharmacy: from $109 a month on a 12-month plan, with the online visit and shipping included. Compounded BPC-157 is not FDA-approved, and results and safety are still unproven.

Is BPC-157 on the 2026 WADA Prohibited List?

Yes-functionally. The 2026 list does not print “BPC-157” by name, but WADA has confirmed the peptide falls under S0, which bans “any pharmacological substance that is not approved by any governmental regulatory health authority for human therapeutic use.” Because no country’s regulator has approved BPC-157 as a drug, it meets the S0 definition.

The 2026 Prohibited List and Summary of Major Modifications note that S0 covers “all non-approved peptides.” Laboratories accredited by WADA receive technical letters clarifying substances that must be reported, and BPC-157 is on that internal reference list. Athletes cannot claim ignorance if it is detected.

Why WADA Classifies BPC-157 as S0

WADA’s rationale is primarily the lack of regulatory approval and human safety data. The S0 category is a catch-all for experimental drugs with no established medical use. Because BPC-157 is still in pre-approval development stages, it lacks the toxicology data WADA requires to exempt a substance.

Performance-enhancement concern: Animal studies report faster soft-tissue healing, an effect that could give an injured athlete an unfair advantage by shortening rehabilitation time (Vasireddi et al., 2025). Until robust human data prove otherwise, WADA treats the peptide as potentially performance-enhancing.

Health-risk concern: Review articles flag the absence of dose-finding and long-term human safety trials (Józwiak et al., 2025). WADA’s Code allows a ban if a substance both lacks approval and poses an unknown health risk.

USADA Guidance and Therapeutic Use Exemptions

USADA Athlete Advisories explicitly warn that BPC-157 is prohibited at all times. The agency’s Global Drug Reference Online (GlobalDRO) database returns “Prohibited” when athletes search for BPC-157.

TUE prospects are slim. To grant a Therapeutic Use Exemption, an athlete must prove (1) a diagnosed condition, (2) no reasonable alternative treatment, and (3) evidence the drug will not enhance performance beyond returning to normal health. Because alternative, approved therapies for tendon healing exist (physiotherapy, platelet-rich plasma, surgical repair), USADA panels have historically denied TUE requests for experimental peptides.

If an athlete thinks BPC-157 is medically necessary, they must submit a TUE application before using the drug and await written approval. Post-test emergency TUEs are rarely granted and require overwhelming medical documentation.

Drug-Test Detection Window and Lab Thresholds

No minimum reporting threshold exists: any amount triggers an Adverse Analytical Finding. Because compounded products vary in strength, predicting clearance time is risky. Our separate guide on BPC-157’s half-life explains why elimination can differ between individuals.

Real-World Violation Cases

Since 2023 at least three publicly reported anti-doping cases have involved BPC-157:

• Mixed-martial-arts athlete (USA, 2023): received a two-year suspension after an out-of-competition sample tested positive.
• Professional cyclist (EU, 2024): accepted a 30-month ban; argued lack of intent, but strict liability applied.
• Collegiate wrestler (NCAA, 2025): declared supplement use; one-year ineligibility under NCAA Bylaw 31.

These precedents underscore that intent, prescription status, and retailer claims do not exempt athletes from sanctions.

How Athletes Can Reduce the Risk of a Violation

Know your testing pool: Verify whether your federation or event uses the WADA List. Even some unsanctioned events now contract labs that follow WADA standards.

Read supplement labels critically: Several “healing stacks” and “joint repair” products list BPC-157 or “Pentadecapeptide” as an ingredient. Under strict liability, a contaminated supplement is not a defense.

Keep prescriptions and batch records: If your physician prescribes compounded BPC-157, ask the pharmacy for a certificate of analysis and lot number. Although this does not make the drug permissible, it helps establish diligence if you later apply for a TUE.

Consider approved alternatives: Physical therapy, eccentric loading programs, and platelet-rich plasma injections have published human data for tendon recovery and are allowed under WADA rules.

⚠️ Unsure about your specific sport?

Contact your national anti-doping organization or consult GlobalDRO before starting any new medication. A five-minute search can prevent a multi-year ban.